Compare PBHC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBHC | PMN |
|---|---|---|
| Founded | 1859 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.8M | 115.5M |
| IPO Year | 2014 | 2022 |
| Metric | PBHC | PMN |
|---|---|---|
| Price | $16.26 | $15.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 22.6K | ★ 55.9K |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 46.25 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $0.29 |
| 52 Week High | $17.40 | $27.40 |
| Indicator | PBHC | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 67.94 |
| Support Level | $13.74 | $8.79 |
| Resistance Level | $17.17 | $19.85 |
| Average True Range (ATR) | 0.78 | 1.30 |
| MACD | -0.07 | 0.15 |
| Stochastic Oscillator | 50.31 | 90.79 |
Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.